PRECISION BIOSCIENCES
LIVE

Serial Number

97117501

Owner

Precision BioSciences, Inc.

Attorney

Eva Gullick Frongello

First Use Date

Feb 11, 2008

Filing Date

Nov 10, 2021

Add to watchlist:

No watchlists yet
View on USPTO

PRECISION BIOSCIENCES Trademark

Serial Number: 97117501 • Registration: 7034223

PRECISION BIOSCIENCES is a trademark filed by Precision BioSciences, Inc. on November 10, 2021. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

Precision BioSciences, Inc. (8 trademarks)

Dibrell Building, Suite A-100
Durham, NC 277013712

Entity Type: 03

Trademark Details

Filing Date

November 10, 2021

Registration Date

April 25, 2023

First Use Anywhere

February 11, 2008

First Use in Commerce

February 11, 2008

Published for Opposition

December 20, 2022

Goods & Services

pharmaceutical preparations, namely, cell therapy products utilizing t-cell therapy for use in treating disease; cell-based immunotherapeutic treatment by way of genetically modified cells for use in human therapeutics and the treatment of cancer; pharmaceuticals for the treatment of cancer; pharmaceutical preparations in the nature of genetically modified cells, namely, genetically modified immune cells for use in human therapeutics and in the treatment of cancer; pharmaceutical and biological preparations based on gene, genome and cellular editing, modulation, modification, engineering, regulation, repair and therapy for use in human therapeutics, namely, therapeutic pharmaceuticals developed through genome modifications for the treatment of cardiovascular, central nervous system, endocrine, gastrointestinal, genetic immunological, infectious, inflammatory, menopausal, metabolic, autoimmune, musculoskeletal, neurological, ophthalmological, psychiatric, respiratory, urogenital, urological, hematologic and viral diseases and disorders; pharmaceutical preparations, namely, therapeutic pharmaceuticals developed through genome modifications for the treatment of erectile dysfunction, sexual dysfunction, cancer, pain and diabetes; pharmaceutical preparations, namely, therapeutic pharmaceuticals developed through genome modifications, namely, antifungal preparations, dermatological preparations, smoking cessation preparations and tissue repair preparations; engineered nucleic acids, viral vectors, non-viral vectors, gene therapy vectors, gene editing vectors, genetically modified cells, engineered proteins for multiplexed gene editing, mRNA and recombinant adeno-associated virus (AAV) vectors for delivery of therapeutic DNA or mRNA sequences to cells, antibody preparations, CAR T-cell preparations, T-cell preparations, B-cell preparations, Treg preparations, and NK cell preparations, all for clinical use, medical use, clinical laboratory use, and medical laboratory use

genome editing reagents for research purposes; Chemical, biochemical, biotechnological products intended for industry, agriculture, horticulture, namely, polypeptides for in vivo and in vitro genetic engineering, natural and engineered meganucleases and endonucleases, nucleic acid vectors, molecular scissors; chemical, biochemical, biotechnological and bacteriological products intended for research laboratories and control laboratories, namely, polypeptides for in vivo and in vitro genetic engineering; Biochemicals and biologics, namely, engineered proteins for gene regulation, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, gene modification, and gene correction, all for use in scientific research, pharmaceutical research, agricultural biotechnology, diagnostics, and industrial biotechnology; engineered proteins for use in scientific research and analysis relating to genetic diseases, gene therapy, and cell therapy; biochemicals and biologics, namely, engineered nucleic acids, viral vectors, non-viral vectors, gene therapy vectors, gene editing vectors, genetically modified cells, engineered proteins for multiplexed gene editing, mRNA and recombinant adeno-associated virus (AAV) vectors for delivery of therapeutic DNA or mRNA sequences to cells, antibody preparations, CAR T-cell preparations, T-cell preparations, B-cell preparations, Treg preparations, and NK cell preparations, all for use in scientific research and analysis and diagno

Medical services, namely, cellular immunotherapy treatments utilizing chimeric antigen receptor t cells for use in treating disease, namely, the treatment of cancer

research in the fields of genome editing, gene editing, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, genetic disease, gene therapy and cell therapy; pharmaceutical research and development services; Scientific research; scientific research in genetic, medical, pharmaceutical and veterinary fields; scientific research in chemistry, biology, biochemistry, molecular biology, bacteriology; scientific analysis in the field of immunotherapy; scientific research in the field of cellular immunotherapy utilizing chimeric antigen receptor t cells for use in treating cancer

Filing History

APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
May 8, 2023 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
May 8, 2023 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
May 8, 2023 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
May 8, 2023 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
May 8, 2023 COAR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Apr 25, 2023 NRCC
REGISTERED-PRINCIPAL REGISTER
Apr 25, 2023 R.PR
ATTORNEY REVIEW COMPLETED
Mar 6, 2023 ATRV
LETTER OF PROTEST EVIDENCE REVIEWED-NO FURTHER ACTION TAKEN
Mar 6, 2023 LOPR
JURISDICTION RESTORED TO EXAMINING ATTORNEY
Mar 6, 2023 JURT
EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
Mar 1, 2023 ETOP
EXTENSION OF TIME TO OPPOSE RECEIVED
Jan 18, 2023 ETOF
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 20, 2022 NPUB
PUBLISHED FOR OPPOSITION
Dec 20, 2022 PUBO
LETTER OF PROTEST EVIDENCE FORWARDED
Dec 15, 2022 LOPT
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 30, 2022 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 17, 2022 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 2, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 2, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 2, 2022 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
May 12, 2022 GNRN
NON-FINAL ACTION E-MAILED
May 12, 2022 GNRT
NON-FINAL ACTION WRITTEN
May 12, 2022 CNRT
ASSIGNED TO EXAMINER
May 10, 2022 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 17, 2021 NWOS
NEW APPLICATION ENTERED
Nov 13, 2021 NWAP